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Abstract 
Background: In vitro expanded mesenchymal stromal cells (MSCs) are increasingly used as experimental cellular 
therapy. However, there have been concerns regarding the safety of their use, particularly with regard to possible 
oncogenic transformation. MSCs are the hypothesized precursor cells of high‑grade osteosarcoma, a tumor with 
often complex karyotypes occurring mainly in adolescents and young adults.
Methods: To determine if MSCs from osteosarcoma patients could be predisposed to malignant transformation 
we cultured MSCs of nine osteosarcoma patients and five healthy donors for an average of 649 days (range 601–
679 days). Also, we compared MSCs derived from osteosarcoma patients at diagnosis and from healthy donors using 
genome wide gene expression profiling.
Results: Upon increasing passage, increasing frequencies of binucleate cells were detected, but no increase in 
proliferation suggestive of malignant transformation occurred in MSCs from either patients or donors. Hematopoietic 
cell specific Lyn substrate 1 (HLCS1) was differentially expressed (fold change 0.25, P value 0.0005) between MSCs of 
osteosarcoma patients (n = 14) and healthy donors (n = 9).
Conclusions: This study shows that although HCLS1 expression was downregulated in MSCs of osteosarcoma 
patients and binucleate cells were present in both patient and donor derived MSCs, there was no evidence of neo‑
plastic changes to occur during long‑term culture.
© 2015 Buddingh et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Mesenchymal stromal cells (MSCs) are increasingly used 
as experimental cellular therapy in a wide range of con-
ditions, such as graft-versus-host disease in the context 
of allogeneic bone marrow transplantation, auto-immune 
diseases and for regenerative purposes in for example 
myocardial injury or cartilage defects [1–6]. However, 
since MSCs have to be expanded in vitro to achieve suf-
ficient numbers, there have been concerns regarding the 
safety of their use, particularly with regard to possible 
oncogenic transformation [7]. Cultured murine MSCs 
readily transform and form sarcoma-like tumors in vivo 
[8–12]. Similarly, MSCs derived from rhesus macaques 
become polyploid and subsequently aneuploid during 
long-term culture [13]. In contrast, human MSCs appear 
resistant to spontaneous in  vitro transformation [14]. 
Studies reporting that human MSCs undergo malignant 
transformation in  vitro have been retracted because of 
cross-contamination issues [15–20]. Despite the appar-
ent difference between human and murine MSCs in their 
propensity to spontaneously transform in vitro, concerns 
remain. MSCs are hypothesized to be the precursor cells 
of high-grade osteosarcoma (OS) and a patient trans-
planted with bone marrow (containing hematopoietic 
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stem cells and MSCs) from a sibling was diagnosed with 
OS originating from donor stem cells 17 years later [21]. 
This case demonstrates that donor-derived (pre-) cancer-
ous MSCs can survive in a host and cause disease many 
years later. Another cause for concern is the observation 
that cultured MSCs can acquire chromosomal aberra-
tions, although these do not seem to confer a selective 
growth advantage in vitro [22, 23].
High-grade osteosarcoma is a malignant primary bone 
tumor which often occurs at a relatively young age [24]. 
OS tumor cells are characterized by aneuploid karyo-
types and gross chromosomal instability [25]. Such highly 
complex chromosomal rearrangements can occur as a 
result of a single catastrophic event, termed chromoth-
ripsis [26, 27]. However, this probably has to occur in a 
susceptible background, either as a genetic predisposition 
or acquired as a de novo event. In a murine model failed 
cytokinesis can lead to tetraploidy and subsequent tumo-
rigenesis only in a p53 deficient host [28]. We previously 
showed loss of CDKN2A/p16 protein expression in tetra-
ploid tumorigenic murine MSCs [9]. We hypothesized 
that normal MSCs from OS patients could be predis-
posed to malignant transformation, and performed long 
term in vitro culture and genome wide expression profil-
ing of early passage MSCs from OS patients and healthy 
donors. Here we show that OS patient-derived MSCs do 
not transform in  vitro, confirming previous reports in 
healthy individuals that spontaneous transformation of 
human MSCs in vitro is an extremely unlikely event.
Methods
Patients
Characteristics of OS patients and healthy stem cell 
donors can be found in Table 1. Bone marrow cells of OS 
patients were harvested under general anesthesia prior 
to start of the chemotherapeutic treatment. The site of 
MSC harvest (iliac crest) was different from the loca-
tion of the primary tumor (metaphyseal ends of the long 
bones) in all cases. Healthy donors were either identical 
sibling donors for patients with malignant or benign dis-
ease requiring hematopoietic stem cell transplantation; 
or haploidentical donors for either hematopoietical stem 
Table 1 Characteristics of osteosarcoma patients (OS) and healthy donors (HD) and overview of experiments
UI unique identifier.
Culture OS (UI)/HD Sex Age (years) Histology Location of the primary tumor Included in experiment
Microarray qPCR Long-term culture
001OS OS (352) M 12 Osteoblastic Distal femur Y Y Y
002OS OS (340) F 13 Osteoblastic Distal femur Y Y Y
003OS OS (376) F 13 Telangiectatic Distal femur Y Y Y
004OS OS (377) F 14 Sclerosing Proximal tibia Y Y Y
005OS OS (348) F 15 Telangiectatic Distal tibia N N Y
006OS OS (349) M 8 Osteoblastic Distal femur Y Y Y
007OS OS (350) F 15 Osteoblastic Distal femur N N Y
008OS OS (378) F 9 Osteoblastic Proximal humerus Y Y Y
009OS OS (382) M 15 Chondroblastic Proximal humerus Y Y Y
010OS OS (388) M 14 Osteoblastic Proximal humerus N Y N
011OS OS (391) F 14 Osteoblastic Proximal tibia N Y N
012OS OS (394) F 5 Osteoblastic Distal femur N Y N
013OS OS (393) F 14 Osteoblastic Distal femur N Y N
014OS OS (395) M 10 Sclerosing Distal femur N Y N
015OS OS (396) M 13 Osteoblastic Distal femur N Y N
016OS OS (402) F 15 Sclerosing Proximal tibia N Y N
HB HD (HB) M 15 Y Y Y
HD3 HD (HD3) F 27 Y Y Y
HD5 HD (HD5) M 50 Y Y Y
MH HD (MH) M 15 Y Y Y
TD1 HD (TD1) F 11 Y Y Y
TD2 HD (TD2) F 43 N Y N
TD3 HD (TD3) F 43 N Y N
TD4 HD (TD4) F 25 N Y N
TD5 HD (TD5) M 5 N Y N
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cell transplantation or the therapeutic infusion of MSCs 
for steroid-resistant graft-versus-host disease. Written 
informed consent was obtained from all patients and 
donors prior to bone marrow harvesting. The study was 
approved by the Institutional Review Board on Medi-
cal Ethics [LUMC Medical Ethics Committee (CME), 
P06.152].
Mesenchymal stromal cell cultures
Bone marrow derived mononuclear cells were obtained 
from 5 to 15  mL of heparinized bone marrow aspirate 
by density gradient centrifugation on Ficoll. Cells were 
plated on non-coated 75 cm2 polystyrene flasks at a cell 
density of 160,000/cm2 in complete culture medium 
(LG-DMEM; Invitrogen, Paisley, UK) supplemented with 
penicillin/streptomycin (Invitrogen) and 10% fetal bovine 
serum (FBS; HyClone, Verviers, Belgium). We used a 
characterized and defined FBS batch preselected for its 
potential to support MSC expansion and continued to 
use this specific batch throughout the culture period. 
MSCs were plastic adherent and had spindle shaped 
morphology. Chondrogenic, adipogenic and osteoblas-
tic differentiation were performed as described earlier 
[29]. Medium was refreshed twice a week and cells were 
replated when reaching 80–90% confluence at a den-
sity of 4,000/cm2. The first nine OS patient and first five 
healthy donor MSC samples that were obtained were 
cultured long-term, the subsequent samples were used 
for confirmatory mRNA expression analysis (Table  1). 
Morphology of the cells was recorded and population 
doublings per passage (PD) were calculated using the 
log ratio of the harvesting cell count (N) to the starting 
(baseline) count (X0), divided by the log of 2 (PD = [log 
(N/X0)]/log 2).
Flow cytometry
Expression of the cell surface markers CD73, CD90 and 
CD105 and absence of hematopoietic markers on MSCs 
was determined using flow cytometry, according to the 
statement by the International Society for Cellular Ther-
apy [30]. Cells were detached using Trypsin/EDTA and 
washed in PBS/0.05% bovine serum albumin. Antibodies 
used were (FITC) conjugated anti-CD86-fluorescein iso-
thiocyanate (FITC) (cat. no. 555657), anti-HLA-DR-FITC 
(cat. no. 347400), anti-CD31-phycoerythrin (PE) (cat 
no 555446), anti-CD34-PE (cat no 348057), anti-CD73-
PE (cat no 550257), anti-CD90-PE (cat no 555596), 
anti-CD3-peridinin chlorophyll protein(PerCP)-Cy5.5 
(cat no 332771), anti-CD45-PerCPCy5.5 (cat no 332784), 
all from BD (San Diego, CA, USA) and anti-CD105-PE 
(cat no SN6), from Ancell (Bayport, MN, USA). Flow 
cytometry was performed on a FACScalibur, and ana-
lyzed using Cellquest software (both Becton–Dickinson). 
Mean fluorescence intensity (MFI) ratio was calculated 
by determining the MFI of the specific staining relative to 
the MFI of the appropriate isotype control staining.
Analysis of binucleate cells
MSCs were grown on coverslips. Coverslips were washed 
with PBS and fixed in 4% PFA. Coverslips were incubated 
for 10  min in 1 μg/mL acridine orange (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) to stain cytoplasm and 
1 μg/mL wheat-germ agglutinin with an Alexa Fluor® 594 
conjugate (Invitrogen) in PBS to stain cell membranes. 
Following washes in PBS, coverslips were mounted using 
Vectashield with DAPI (Vector laboratories, Burlingame, 
CA, USA) to stain nuclei. Images were acquired using a 
COHU 4910 series monochrome CCD camera (COHU, 
San Diego, CA, USA) attached to a DM fluorescence 
microscope (Leica, Wetzlar, Germany) and analyzed 
using ImageJ software with the Cell Counter plug-in 
(National Institute of Mental Health, Bethesda, MD, 
USA).
RNA isolation
RNA was isolated from frozen cell pellets of at least 
1*10e6 undifferentiated MSCs at passage 2–5 using TRI-
zol reagent (Invitrogen). Cells were lysed in TRIzol, fol-
lowed by phase separation in chloroform, precipitation 
using 2-propanolol and washing in 75% ethanol. RNA 
clean-up was performed using the QIAGEN Rneasy mini 
kit (Venlo, the Netherlands) with on-column DNAse 
treatment. RNA quality and concentration were meas-
ured using an Agilent 2100 Bioanalyzer (Santa Clara, CA, 
USA) and Nanodrop ND-1000 (Thermo Fisher Scientific, 
Waltham, MA, USA), respectively.
cDNA synthesis, cRNA amplification, and Illumina Human 
v2.0 Expression BeadChip hybridization
Gene expression profiling was performed using Human-6 
v2 Expression BeadChips (San Diego, CA, USA) contain-
ing >48,000 transcript probes. Synthesis of cDNA, cRNA 
amplification, and hybridization of cRNA onto the Illu-
mina Human v2.0 Expression BeadChips were performed 
as described previously [31, 32].
qPCR
cDNA synthesis for qPCR was performed as described 
earlier [32]. qPCR was performed using the iQ™ SYBR® 
Green Supermix (Bio-Rad, Hercules, CA, USA) accord-
ing to the manufacture’s instructions, reverse tran-
scriptase negative (RT−) and H2O controls were taken 
along for each sample. For normalization, three genes 
with stable expression in the microarray experiments 
were chosen (CPSF6, GPR108 and CAPNS1). Data were 
normalized by geometric mean expression levels of the 
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three reference genes using geNorm (http://medgen.
ugent.be/jvdesomp/genorm/). Primer sequences can be 
found in Additional file 1: Table S1. A standard curve was 
taken along for each primer set and used for quantifica-
tion, PCR efficiencies ranged from 93 to 104%.
Karyotyping
Six early passage samples (three derived from OS 
patients, three derived from healthy donors) were sub-
jected to a multicolor FISH based karyotyping test 
(COBRA-FISH) as described earlier [33]. From each 
sample at least 20 metaphase cells were recorded and 
analyzed.
Statistical analysis
Microarray data were normalized using the Cubic Spline 
normalization method with the Illumina BeadStudio 
Gene Expression Module. Microarray data are available 
at GEO using the accession no. GSE42572. Statistical 
analysis of microarray was performed using Significance 
Analysis for Microarrays, using a false discovery rate of 
20% (SAM, http://www-stat.stanford.edu/~tibs/SAM/) 
[34]. Univariate statistical analyses were performed using 
GraphPad Prism software (version 5.01, La Jolla, CA, 
USA). Two-sided P values lower than 0.05 were deter-
mined to be significant.
Results
MSCs of OS patients and healthy donors do not differ 
in expression of cell surface markers or differentiation 
capacity
We tested the MSC cultures from OS patients and 
healthy donors for phenotypic markers and functional-
ity. Samples from 16/16 patients and 9/9 controls were 
able to differentiate into chondrogenic (Additional file 2: 
Figure S1A), adipogenic (Additional file  2: Figures S1B 
and C) and osteoblastic lineages (Additional file  2: Fig-
ures S1D and E). Also, all MSC cultures expressed CD73, 
CD90 and CD105 and lacked expression of hematopoi-
etic markers (Additional file  2: Figure S1F). Level of 
expression of CD73, CD90 and CD105 as determined 
by MFI-ratios (specific staining/isotype control) did not 
differ between MSC cultures derived from OS patients 
and healthy donors. Early passage samples from three OS 
patient derived MSCs and three healthy donor derived 
MSCs were karyotyped; no structural or numerical aber-
rations were observed in the analyzed samples (Addi-
tional file 3: Figure S2): MSC001: 46,XY (26 metaphases), 
MSC003: 46,XX (27 metaphases), MSC008:46,XX (22 
metaphases), MSC-HB: 46,XY (21 metaphases), MSC-
MH: 46,XY (20 metaphases), MSC-TD: 46,XX (21 meta-
phases). Late passage cells could not be karyotypically 
analyzed due to the low numbers of dividing cells.
Long-term in vitro culture of MSCs results in increased 
binucleation but not in malignant transformation
MSCs of nine OS patients and five healthy donors were 
long term cultured (average number of days in culture 
649, range 601–679  days). From each individual sam-
ple, duplicate cultures were established. There were no 
significant differences between growth rate, cumulative 
population doublings (median cumulative population 
doublings OS patients 34 vs. healthy donors 39; P value 
Mann–Whitney U test 0.70), passage number at termina-
tion of culture (mean passage number OS patients 21 vs. 
healthy donors 23; P value Mann–Whitney U test 0.74) 
or time to growth arrest (median days to growth arrest 
OS patients 441  days vs. healthy donors 222  days; P 
value Mann–Whitney U test 0.15) between MSCs of OS 
patients and healthy donors. The cumulative population 
doublings are shown in Figure  1 (averages of the dupli-
cate cultures are shown per sample). All cultures exhib-
ited rapid exponential growth in the first few passages. 
Later, proliferation slowed down and eventually stopped, 
characteristic of cultured cells in crisis. At termination of 
the cultures, viable cells were present in all samples. Cul-
tures were terminated at the end of the growth curves. 
At this point, in none of the cultures there was evidence 
of cells escaping the crisis by an increase in proliferation 
and corresponding morphological changes indicative for 
spontaneous in vitro malignant transformation.
Morphology of the cells was inspected with every pas-
sage. Low passage cells were spindle-shaped, higher pas-
sage cells were larger. Upon increasing passage number, 
increasing frequencies of binucleate cells were noted 
using phase contrast microscopy. To quantify binuclea-
tion, cells were grown on coverslips and cytoplasm, cell 
membranes and nuclei were stained. Mono- and binucle-
ate cells were counted (Figure  2a–d). There was no dif-
ference in percentage of binucleate cells between MSCs 
derived from OS patients and healthy donors (Figure 2e).
Figure 1 Cumulative population doublings of cultured MSCs from 
nine osteosarcoma (OS) patients and five healthy donors. All samples 
were grown in duplicate, averages of each duplicate are shown.
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HCLS1 mRNA expression is downregulated in OS patient 
derived MSCs
Using microarray gene expression analysis, five genes 
were found to be differentially expressed between 
early passage healthy donor derived MSCs (n =  5) and 
OS patient derived MSCs (n  =  7), with a false discov-
ery rate of 20%. Expression of HCLS1, ADM, EEF1A1, 
LOC644739 (or WASF4) and LOC441155 was lower 
in patient derived MSCs as compared to healthy donor 
derived MSCs. To perform simultaneous technical and 
biological validation of the microarray results, the origi-
nal low passage MSC samples were recultured and the 
original series expanded to now include four additional 
healthy donor derived MSCs (total of n =  9) and seven 
additional OS patient derived MSCs (total of n  =  14). 
Four of the differentially expressed genes were validated 
using qPCR: hematopoietic cell specific Lyn substrate 1 
(HCLS1), adrenomedullin (ADM), eukaryotic translation 
elongation factor 1 alpha 1 (EEF1A1) and LOC644739 (or 
WAS protein family, member 4; WASF4). LOC441155 is 
a pseudogene for which we did not succeed in design-
ing a sufficiently specific and efficient primer pair. In this 
second, newly cultured and expanded series, expression 
of HCLS1 was significantly lower in OS patient derived 
MSCs as compared to healthy donor derived MSCs (Fig-
ure 3, fold change 0.25, P value 0.0005). The other genes 
were not differentially expressed in this series, perhaps 
because this was a newly expanded batch of cells. We 
tried to determine if the observed difference in HCLS1 
expression was also true at the protein level. Although 
HCLS1 protein could be clearly detected in the posi-
tive control cell line Jurkat, we were unable to reproduc-
ibly detect HCLS1 in MSCs. For five OS patients we had 
mRNA available from both bone-marrow derived MSCs 
and the primary tumor. In these samples, expression of 
HCLS1 was higher in tumor tissue as compared to MSCs, 
but there was no correlation between level of expression 
of HCLS1 in low passage MSCs and in the corresponding 
tumor tissue.
Discussion
In recent years, MSCs have gained increasing interest 
as a therapeutic modality for immune modulatory and 
regenerative purposes [1–4]. In order to achieve suffi-
cient numbers of cells for therapeutic utility, MSCs need 
to be expanded in vitro prior to infusion. Since long-term 
culture of non-human MSCs can result in oncogenic 
transformation and the occurrence of sarcomas in the 
receiving hosts, there is ongoing debate regarding the 
safety of using cultured MSCs in clinical studies [35]. In 
the present study, we compared human MSCs derived 
from OS patients at diagnosis and from healthy donors 
Figure 2 Increased binucleation upon increasing passage number. To facilitate cell staining and counting of nuclei, cells were grown on glass 
coverslips and stained using wheat‑germ agglutinin (a cell membranes), acridine orange (b cytoplasm) and DAPI (c nuclei), shown in ×100 
magnification. d Overlay with cell membrane in red, cytoplasm in green and nuclei in blue. A representative example of a high passage binucleate 
cell is shown. Note also the presence of a micronucleus (panel c). e Upon increasing passage number, more binucleate cells were noted, but no 
differences were seen between healthy donor‑derived and osteosarcoma (OS) patient‑derived MSCs (Kruskal–Wallis test P value <0.0001, Dunn’s 
post‑test compared to early passage cells; P value **<0.01; ***<0.001.
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to answer two questions. First, do human MSCs trans-
form to a malignant phenotype when cultured in  vitro, 
as has been shown for murine MSCs? Second, are MSCs 
derived from OS patients more likely to transform than 
healthy donor derived MSCs?
MSCs from patients and controls exhibited similar 
growth patterns during long-term in  vitro culture. Dur-
ing this time, all cultures reached a plateau in prolifera-
tion characteristic of cells in crisis. In contrast to what we 
have previously observed in murine MSCs [9], we never 
observed escape of this crisis by a rapidly dividing cell 
population with changed morphology, even after almost 
2 years of continuous culture. There were no phenotypical 
or functional differences between OS patient derived and 
healthy donor derived MSCs and early passage karyotypes 
were normal in both groups. Differentiation capacity and 
expression of specific cell surface markers was similar.
During prolonged culture, progressive shorten-
ing of telomeres occurs [36]. This can cause anaphase 
chromatin bridges, resulting in failed cytokinesis and 
consequently in binucleate cells [37]. In the context of 
loss of expression or function of tumor suppressor pro-
teins and corresponding cell cycle checkpoints, tetra-
ploidy and ultimately aneuploidy will occur [28]. Upon 
increasing passage, increasing frequencies of binucle-
ate cells were noted; both in patient derived MSCs and 
healthy donor derived MSCs (Figure  2). However, since 
we did not observe an increase in proliferation in these 
cells despite the presence of increasingly high frequen-
cies of binucleate cells, cell cycle checkpoints were prob-
ably functionally intact, both in MSCs derived from OS 
patients and from healthy donors.
In addition to the functional read-out of long-term cul-
ture, we also performed gene expression analysis on early 
passage cells. Expression of HCLS1 was downregulated in 
MSCs from OS patients as compared to MSCs of healthy 
donors. HCLS1 is primarily known for its role in the sign-
aling cascade that follows B cell receptor activation. It is 
Figure 3 HCLS1 gene expression is lower in MSCs from osteosarcoma patients as compared to healthy donors. Expression of HCLS1 as determined 
by qPCR in bone‑marrow derived MSCs no later than passage 5 is lower in MSCs derived from newly diagnosed osteosarcoma patients (OS; n = 14) 
than in MSCs derived from healthy donors (HD; n = 9). ***P value Mann–Whitney‑U test = 0.0005. Expression levels for EEF1A1, ADM and WASF4 
were not significantly different.
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highly expressed in B-cell derived malignancies and is 
associated with a poor outcome [38, 39]. Further studies 
are needed to determine if HCLS1 might have a tumor 
suppressor function and if its loss of expression in OS 
patients derived MSCs has any relationship to in  vivo 
tumorigenesis. Although we show no functional dif-
ference between healthy donor and OS patient derived 
MSCs, we do not advocate the use of MSCs from known 
cancer patients for clinical purposes. The relevance of 
the differential expression of HCLS1 remains unknown 
and there might be other undetected (pre-) malignant 
alterations.
Both on a transcriptional and on a functional level, 
OS patient and healthy donor derived MSCs were very 
similar. There are several possible explanations for the 
observed similarities between OS patient derived and 
donor derived MSCs. First, we obtained MSCs from the 
iliac crest, while all tumors in our series were located at 
the metaphyseal ends of the long bones. OS occurs at a 
time and place of active growth and perhaps this pro-
proliferative microenvironment (with high expression 
of growth factors) is an essential prerequisite for onco-
genic transformation of MSCs. Second, (pre-) oncogenic 
alterations may be present in only one or a few local mes-
enchymal tumor precursor cells and not in MSCs at a 
distant site such as the iliac crest. This could be due to 
somatic mosaicism, similar to what has been shown for 
the enchondromatosis syndromes Ollier disease and 
Maffucci syndrome [40]. Third, according to the ‘multiple 
hit hypothesis’, there may not have been sufficient ‘hits’ 
for in vitro transformation to occur, even if relevant pre-
disposing alterations are present. Ionizing radiation is a 
well-known risk factor for developing osteosarcoma and 
low-dose radiation facilitates oncogenic transformation 
in telomerase-transduced immortalized MSCs [41, 42]. 
Perhaps one or two additional ‘hits’ (for example loss of 
cell cycle checkpoint control or radiation-induced DNA 
damage) would be enough for oncogenic transformation 
to occur.
Fourth, pre-malignant alterations may have been pre-
sent in only a few cells, which would not lead to large 
enough differences in gene expression to be picked up 
by genome wide expression analysis. Novel techniques 
to study genetic alterations at a single cell level might be 
able to pick up these rare events [43, 44]. Finally, although 
there is compelling evidence to suggest MSCs are the 
precursor cells for human OS, this has not yet been une-
quivocally proven.
Conclusions
During long-term in  vitro culture of human OS patient 
and healthy donor derived MSCs, there was no evidence 
for neoplastic changes to occur. We could not confirm 
our hypothesis that MSCs of OS patients might have 
a higher propensity to oncogenic transformation than 
healthy donor derived MSCs. In contrast to what has 
been reported for other species, under the tested condi-
tions, human MSCs do not easily transform. Although 
we cannot exclude the occurrence of low frequencies of 
cells with genomic alterations, we did not see a selective 
growth advantage of aberrant cells nor did we observe 
karyotypic abnormalities in low passage cells. This data 
supports the currently held view that administration 
of low passage cultured healthy donor derived human 
MSCs for therapeutic purposes is unlikely to result in 
sarcomas in the host.
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